Mankind Pharma signs pact with China co to sell 2 insulin drugs in India
This story was originally published at 14:09 IST on 20 August 2026
Register to read our real-time news.Informist, Thursday, Aug. 20, 2026
--Mankind Pharma signs licence pact with Chongqing Chenan for 2 insulin drugs
--Mankind Pharma, Chongqing Chenan in pact to sell 2 insulin drugs in India
NEW DELHI – Mankind Pharma Ltd. Thursday said it has entered into an exclusive in-licensing and marketing agreement with China-based Chongqing Chenan Biopharmaceutical Co. Ltd. for commercialisation of insulin degludec and insulin degludec + aspart combination in India, the company said in the exchange filing.
For the June quarter, Mankind Pharma had reported a consolidated net profit of INR 5.68 billion on revenues of INR 40.31 billion. At 1350 IST, shares of the company traded at INR 2,403.40 on the National Stock Exchange, up 0.4%. End
IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT
Reported by Gunjan Rajput
Edited by Akul Nishant Akhoury
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (11) 4220-1000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
